Charles River Laboratories acquisition of Vigene Biosciences
Davis Polk is advising Charles River Laboratories International, Inc. in connection with its $292.5 million acquisition of Vigene Biosciences, Inc. The transaction includes contingent additional payments of up to $57.5 million based on future performance. The transaction is expected to close in the beginning of the third quarter of 2021, subject to regulatory requirements and customary closing conditions.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Vigene Biosciences is a U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.
The Davis Polk corporate team includes partner Michael Davis and associates Jamie Kurtz and Amanda R. Simmons. The tax team includes partner William A. Curran and associate Liang Zhang. Partner Kyoko Takahashi Lin and associate Tessa Patti are providing executive compensation advice. Partner David R. Bauer and associate Christopher C. Woller are providing intellectual property advice. The real estate team includes associate Gregory D. Crane. All members of the Davis Polk team are based in the New York office.